| Literature DB >> 31083446 |
Bilal Ahmad1, Masaud Shah2, Sangdun Choi3.
Abstract
Marine flora is taxonomically diverse, biologically active, and chemically unique. It is an excellent resource, which offers great opportunities for the discovery of new biopharmaceuticals such as immunomodulators and drugs targeting cancerous, inflammatory, microbial, and fungal diseases. The ability of some marine molecules to mediate specific inhibitory activities has been demonstrated in a range of cellular processes, including apoptosis, angiogenesis, and cell migration and adhesion. Immunomodulators have been shown to have significant therapeutic effects on immune-mediated diseases, but the search for safe and effective immunotherapies for other diseases such as sinusitis, atopic dermatitis, rheumatoid arthritis, asthma and allergies is ongoing. This review focuses on the marine-originated bioactive molecules with immunomodulatory potential, with a particular focus on the molecular mechanisms of specific agents with respect to their targets. It also addresses the commercial utilization of these compounds for possible drug improvement using metabolic engineering and genomics.Entities:
Keywords: Toll-like receptor; immunotherapy; inflammation; marine drug; marine flora
Mesh:
Substances:
Year: 2019 PMID: 31083446 PMCID: PMC6562586 DOI: 10.3390/md17050282
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structure of anti-inflammatory and immunomodulatory marine-derived compounds.
Marine bacteria and their therapeutic chemical constituents.
| Bacterial Species | Chemical(s) | Immunomodulatory Activity | Ref(s) |
|---|---|---|---|
|
| Cyclic depsipeptide | In vivo activity in the plasmocytoma murine model of xenograft. Applidine exhibits antimyeloma activity in vivo. | [ |
| Lestaurtinib (Alkaloid) | Potent PKC and calmodulin inhibitor. Prevents myelin oligoglycoprotein induced encephalomyelitis in vivo. | [ | |
|
| Bryostatin polyketide | Exhibits antitumor activity against malignant melanoma. IL-6 and TNF- | [ |
|
| Anti-Micrococcus luteus antibodies | Immunosuppressive potential through the expansion of immunoregulatory T cell subsets. | [ |
|
| Didemnin B (Depsipeptides) | Exhibits strong anti-inflammatory and immunosuppressive activity. The expression of iNOS and NF- | [ |
|
| EPS 1-T14 | Stimulates Th1 cell-mediated immunity. | [ |
|
| EPS TA-1 | Encourages the TLR2-dependent release of TNF- | [ |
|
| Prodigiosin & | Anti-inflammatory. Inhibits the activation of TNF- | [ |
| Diketopiperazines | Anti-inflammatory. Downregulates the release of TNF- | [ | |
|
| Arenamides | Blocks TNF- | [ |
| Aburatubolactams | Antioxidant. Inhibits TPA-induced superoxide anion generation in human neutrophils. | [ | |
| Cyclomarins (Heptapeptides) | Anti-inflammatory. Inhibits oedema and pain in vivo. | [ | |
| Salinamides (Peptides) | Anti-inflammatory on phorbol ester-induced oedema mouse. | [ | |
| Splenocin B | Anti-inflammatory. Potent inhibitors of pro-inflammatory cytokine IL-5, IL-13 and TNF- | [ |
EPS, exopolysaccharide; iNOS, inducible nitric oxide synthase; IL, interleukin; NF-κB nuclear factor-κB; PKC, protein kinase C; TPA, 12-O-tetradecanoylphorbol-13-acetate; TLR, toll-like receptor; TNF, tumor necrosis factor.
Marine cyanobacteria and their therapeutic chemical constituents.
| Cyanobacteria Species | Chemical(s) | Immunomodulatory Activity | Ref(s) |
|---|---|---|---|
|
| CyP | CyP modulates pro-inflammatory effect and inhibits TNF- | [ |
|
| Microcolin-A (Peptides) | Suppresses murine splenocytes and inhibits LFA-1 and ICAM-1 mediated cell adhesion. | [ |
|
| Malyngamide 2 (lipopeptide) | Inhibits production of NO in LPS-primed RAW 264.7 cells. | [ |
|
| Immolina (Polysaccharide) | Reduces TNF- | [ |
|
| Aqueous extract | Anti-inflammatory effects in carrageenan-induced inflammation in rats. | [ |
|
| Grassystatins A-C | Inhibits presentation of T cell antigen and expression of Cathepsin E, IL-17, and IFN- | [ |
CyP, cyanobacterial LPS; ICAM-1, intercellular cell adhesion molecule-1; IFN, interferon; IL, interleukin; LFA-1, lymphocyte function-associated molecule-1; TNF, tumour necrosis factor.
Marine sponges and their therapeutic chemical constituents.
| Sponge Species | Chemical(s) | Immunomodulatory Activity | Ref(s) |
|---|---|---|---|
|
| Simplexides Glycolopids | Inhibits T cell proliferation and induces cytokines and chemokines in a CD1d-dependent manner. | [ |
| Dendroceratida & bolinaquinone (Polyoxygenated sterols) | Inhibits neutrophilic infiltration and IL-1, IL-8, PGE2, COX-2 | [ | |
|
| Contignasterol (Oxygenated sterol) | Inhibits histamine release in mast cells. | [ |
| Petrocortyne A (polyacetylenic alcohols) | Inhibits macrophages, reduces the production of TNF- | [ | |
| Pateamine (Thiazole macrolide) | Specifically targets translation initiation factors. Inhibits eIF4A-eIF4G association and promotes stable ternary complex formation between eIF4A and eIF4B. IL-2 inhibitor. | [ | |
| Callyspongidiol (Polyketide) | Dendritic cell activation with enhanced IL-4 and IL-10 production. | [ | |
|
| Iso-iantheran (Polyketide) | Has implication in tumor or autoimmune diseases. Ionotropic P2Y11 receptor activation. | [ |
|
| Xestobergsterol (Polyhidroxylated steroid) | Inhibits the generation of IP3 and PLC activity and intracellular Ca2 + mobilization. | [ |
|
| Clathriols (Polyoxygenated steroids) | Inhibits superoxide production from neutrophils of hPBMCs. | [ |
|
| Heteronemin (Sesterterpene) | Inhibits TNF- | [ |
|
| Methanolic extract | Exhibits anti-inflammatory activity against carrageen-induced paw inflammation. | [ |
|
| Plakortide P | NO inhibition in LPS stimulated macrophages. | [ |
|
| Methanolic and Chloroform extraction | Reduces IL-8, CXCL10 and VEGF levels and increases IL-4 and IL-10 levels. | [ |
|
| Coscinolactams A-B (Terpenes) & suvanine | PGE2 and NO inhibition in RAW 264.7 cells stimulated by LPS. | [ |
|
| Lobocrassin B | Inhibits LPS-induced BMDC activation by inhibiting TNF- | [ |
|
| Petrosaspongiolide | Inhibits chronic inflammation by lowering the production of eicosanoids and TNF- | [ |
|
| Puupehedione, dipuupehedione, | Exhibits cytotoxic and immunomodulatory potential against A-549 human cancer cell line. | [ |
|
| Terpenes, steroids and lipids | Ethyl acetate extracts from | [ |
|
| Fasciculatin (Sesterterpenes) | Exhibits moderate cytotoxicity and no selectivity in the cancer cell lines. | [ |
|
| Lipopolysaccharides & neolamellarins | [ | |
|
| Solomonsterol A, | [ | |
|
| Discodermolide (Polyhydroxylated lactone) | Inhibits murine T cell proliferation and causes cell cycle arrest in gap2 or mitosis phase of human and murine cell lines. | [ |
|
| Cyclic Tripeptide | In preliminary tests renieramide showed immunomodulating activity. | [ |
|
| Didemnins | Inhibits viral replication in vitro and | |
|
| Girolline | Inhibits of IL-8, NF- | [ |
|
| Callysterol (Sterol) | Potentially inhibits rat hind paw oedema, reduced release of TXB2 from LPS-activated rat brain microglia. | [ |
|
| Alkaloids | Inhibits expression of NF- | [ |
|
| Tedanol (Diterpenoid) | Potent anti-inflammatory action to reduce carrageenan-induced mouse paw oedema. Strong inhibition of COX-2 and iNOS expressions. | [ |
| Halipeptins (Depsipeptide) | Strong anti-inflammatory activity, in vivo and in vitro. | [ | |
|
| Sesterterpenoid | Suppresses the production of LPS-induced PGE2. | [ |
| Fascaplysin (Indole alkaloid) | CDK 4 inhibitor, potential to elicit anti-neuroinflammatory or neuroprotective responses in neuroinflammatory disease models. | [ | |
| Terpioside B (Glycolipid) | Inhibits macrophage iNOS expression. | [ |
AP-1, activator protein; CDK, cyclin-dependent kinase 4; HIF-1, Hypoxia-inducible factor-1; IFN, interferon; IL, interleukin; iNKT, Natural killer T cells with an invariant T cell receptor alpha chain; iNOS, inducible nitric oxide synthase; NF-κB, nuclear factor-κB; PGE2, prostaglandin E2; PLC, phospholipase C; TNF, tumour necrosis factor; TXB2, thromboxane B2; VEGF, Vascular endothelial growth factor.
Marine algal flora and their therapeutic chemical constituents.
| Algal Species | Chemical | Immunomodulatory Activity | Ref(s) |
|---|---|---|---|
|
| Phlorotannin | Inhibits IgE and exhibits anti-degranulation effects; changes Th1/Th2 balance in Brown Norway rat strain. | [ |
|
| Polysaccharides | Stimulates concentration-dependent proliferation of T cells and significant induction of the production of TNF- | [ |
|
| Lectins | Improves the IL-10 induction and induces the immune response of Th2 in mouse splenocytes. | [ |
|
| Enone fatty acids | Inhibits the production of NO, TNF- | [ |
|
| Terpenes, steroids and lipids | Demonstrate chemotactic, phagocytic and intracellular killing of human neutrophils, and show a significant immunostimulatory effect in vivo. | [ |
|
| Laminarin oligosaccharides & | Apoptotic cell death protein was significantly reduced by laminarin oligosaccharides. | [ |
|
| Ethanol extract | Inhibits NO generation and downregulates NF- | [ |
|
| Sulfated | RAW 264.7 cells were stimulated by polysaccharides, which produced considerable NO, and PGE2 induces strong immunomodulation. | [ |
|
| Polysaccharides | Enhanced activity for the proliferative response of spleen cells in endotoxin nonrespondent C3H / HeJ mice. | [ |
|
| Polysaccharides | [ | |
|
| Lipopolysaccharides | [ | |
|
| Fucoidan | Fucoidan enhances phagocytosis and macrophage chemiluminescence. | [ |
|
| Polysaccharides | Extracts of | [ |
|
| Carrageenan | λ-carrageenan showed antitumor activity and lymphocyte activation in mice transplanted tumor. | [ |
|
| Polysaccharides | [ | |
|
| Polysaccharides & | [ | |
|
| trans-ceratospongamide (Peptide) | Potent inhibition of sPLA2 expression in an anti-inflammatory cell model. | [ |
|
| Phlorotannins Dieckol, Eckol | Inhibits LPS-induced NO production, iNOS and COX-2 protein levels and t-BHP-induced ROS generation in RAW 264.7 cells. | [ |
|
| Fucodiphloroethol | Degranulation in RBL-2H3 cells induced by IgE. | [ |
|
| Rhipocephalin (Sesquiterpene) | Bee venom sPLA2 inhibitory activity. | [ |
|
| Exopolysaccharide EPCP1-2 | Regulates the expression of TLR-4, MAPK and NF- | [ |
|
| Sulphated polysaccharide P-KG103. | Activates NO production in a JNK-dependent manner and stimulates cytokines IL-1, IL-6, and TNF- | [ |
|
| Diphlorethohydroxycarmal-ol (Phlorotannin) | Inhibits the IL-6 production and expression of NF- | [ |
|
| Phlorotannin subfraction | Reduces TNF- | [ |
|
| Yessotoxin (Polyketide) | Inhibits macrophage phagocytosis and TNF- | [ |
|
| Pacifenol (Terpenoid) | Anti-inflammatory activity, reduces the production of leukotriene B4 (LTB4) and thromboxane B2 (TXB2). | [ |
|
| Epitaondiol (Terpenoid) | Anti-inflammatory effects, inhibits the release and modulation of the COX pathway eicosanoids (LTB4 and TXB2). | [ |
|
| Lobophorins (Macrolides) | Anti-inflammatory properties. | [ |
|
| Bromohydroquinones | Bee venom sPLA2 inhibitory activity. | [ |
|
| Meroterpene epitaondiol | Potent anti-inflammatory agent with strong activity on TPA induced ear oedema in mice and human neutrophils. | [ |
|
| Bromophenols vidalols | Bee venom sPLA2 inhibitory activity. | [ |
COX, cyclooxygenase; IFN, interferon; IL, interleukin; JNK, c-Jun NH2-terminal kinase; IgE, immunoglobulin E; iNOS, inducible nitric oxide synthase; LKB4; leukotriene B4; LPS, lipopolysaccharide; MAPK; mitogen-activated protein kinase; MCP-1, monocyte chemoattractive protein-1; MIP, macrophage inflammatory protein; NF-kB, nuclear factor-κB; NO, nitric oxide; PGE2, prostaglandin E2; PLA2, phospholipase A; t-BHP, tert-butylhydroperoxide; TLR, toll-like receptor; TNF, tumour necrosis factor; TPA, 12-O-tetradecanoylphorbol13-acetate; TXB2, thromboxane B2.
Marine fungi and their therapeutic chemical constituents.
| Marine Fungi | Chemical(s) | Immunomodulatory Activity | Ref(s) |
|---|---|---|---|
|
| cyclosporine | Calcineurine complex inhibition with cyclophilines. | [ |
|
| Sirolimus macrocyclic lactone | Inhibits IL-2R signal transduction and other cytokine signals. | [ |
| CTD-13C | Semivioxanthin | Regulates expression of TNF- | [ |
| Brevicompanine E | Reduces the production of proinflammatory cytokines induced by LPS. | [ | |
| Citreohybridonol | Suppresses neuroinflammatory enzymes and cytokines associated with NF-кB and MAPK in BV2 cells stimulated by LPS. | [ | |
|
| Azonazine (Dipeptide) | Inhibits the production of NF- | [ |
| Aurantiamide acetate | Exhibits NF- | [ | |
| Isocoumarins | Inhibits the production of NO in LPS-induced RAW 264.7 cells | [ | |
| Xyloketal | Exhibits neuroprotective effect on neonatal hypoxic-ischemic brain injury both in vivo and in vitro. | [ | |
|
| Questinol (Anthraquinone) | Inhibits NO and PGE2 production in LPS-stimulated RAW 264.7 cells. | [ |
| Neoechinulins A and B (Diketopiperazine) | PGE2 and NO generation as well as iNOS and COX2 expression are downregulated. Diminishes IL-1 and TNF- | [ | |
|
| Chaetoglobosin Fex | Suppresses LPS-stimulated IL-6, monocyte chemotactic protein-1, and TNF- | [ |
|
| Pyrenocine A | Inhibits gene expression in LPS-stimulated macrophages due to NF- | [ |
|
| Phlorofucofuroeckol (Phlorotannin) | Inhibits NO and PGE2 production by the suppressing iNOS and COX-2 protein expression. | [ |
CD, cluster of differentiation; COX, cyclooxygenase; IL, interleukin; JNK, c-Jun NH2-terminal kinase; iNOS, inducible nitric oxide synthase; LKB4; leukotriene B4; MAPK; mitogen-activated protein kinase; MHC, major histocompatibility complex; NF-kB, nuclear factor-κB; NO, nitric oxide; PGE2, prostaglandin E2; PLA2, phospholipase A2; TLR, toll-like receptor; TNF, tumor necrosis factor.
Mangroves, corals and other marine creatures and their therapeutic chemical constituents.
| Species | Chemical(s) | Immunomodulatory Activity | Ref(s) |
|---|---|---|---|
|
| Yondelis (Trabectedin) | Reduces the proliferation of monocytes and the differentiation of | [ |
|
| Leaf extract | Inhibits HIV-1 or HIV-2 and reduces acute inflammation. | [ |
|
| Rhizome extract | Inhibits cell proliferation and IL-2, NO, and TNF- | [ |
|
| Diterpene glycosides | Inhibits TPA induced oedema in mouse, MPO release in human PMNs and, NO production in J774 macrophages. | [ |
|
| Peptide ShK | Regulates the function of effector-memory T cells and class-switched memory B cells. | [ |
|
| D-Glucan | Suppresses the production of LPS-induced TNF- | |
|
| Fatty acid | Increases production of NO and PGE2 in RAW 264.7 cells. | [ |
|
| Trypsins | Causes an inhibitory effect on central inflammatory gene ( | [ |
|
| Polysaccharides | Exhibits immunomodulatory action of superoxide dismutase and its possible use as an indicator of immune responses. | [ |
| Fractions of Petroleum ether:ethyl acetate (1:1) | Exhibits immunosuppressive activity in the plaque forming cell assay. | [ | |
|
| Mytilan (Bioglycan) | Mytilan isolated from the mussel mantle | [ |
|
| Convolutamydine A (Oxindole alkaloid) | Inhibits COX-2, iNOS, IL-6, PGE2 and TNF- | [ |
|
| Pregnane-type steroids (Sclerosteroid) | Inhibits the expression of both iNOS and COX-2 proteins in LPS induced macrophages. | [ |
|
| Ergosta-7,22-dien-3-ol | Anti-inflammatory. Effective against iNOS, CHOP and I | [ |
|
| Steroids | Inhibits pro-inflammatory cytokine secretion, including IL-12, p40, IL-6 and TNF- | [ |
|
| Michosterols (Polyoxygenated steroids) | Suppresses the generation of superoxide anion and elastase release in human neutrophils stimulated by N-formyl-methionyl-leucyl-phenylalanine /cytochaslasine B. | [ |
|
| Isoparalemmone (Sesquiterpenoid) | Inhibits iNOS protein expression in activated RAW 264.7 cells. | [ |
|
| Hirsutalins (Diterpenes) | Inhibits LPS-stimulated iNOS protein production. | [ |
|
| Laevigatol | Inhibitory effects on NF- | [ |
|
| Gibberoketosterol (Steroids) | Inhibits the production of iNOS and COX-2 proteins in LPS-stimulated RWA 264.7 cells. | [ |
|
| Pseudopterosins (Diterpene glycosides) | Blocks zymosan-induced eicosanoid release in RAW 264.7 cells. | [ |
|
| Fucosides (Diterpene arabinose glycosides) | Inhibits inflammation in the oedema model induced by 12-O- tetradecanoylphorbol-13-acetate. | [ |
|
| Flesh and ashes of burned shell | Strengthens body’s immune system; sore and wound healing property. | [ |
|
| Shell and flesh | Inhibits the inflammation of the mouth, recurrent aphthous ulcer, and gingivitis. | [ |
|
| Staurosporine & Enzastaurin | Ameliorates neuroinflammation by reducing demyelination and axonal damage. | [ |
|
| Extracts fermented with C. | Inhibits the production of NO in RAW 264.7 cells. | [ |
|
| Capnellene | Inhibits iNOS and COX-2 in IFN- | [ |
|
| Shell powder | Decreases iNOS expression and enhances the function of macrophages. | [ |
|
| Footpad lipid extract | Inhibits ROS, TNF- | [ |
|
| Chloroform extract of the hypobranchial gland | Inhibits the production of NO, downregulated the production of | [ |
|
| Novel omega 3 | Inhibits the biosynthesis of cholesterol, COX-2, TNF-α and PGE. Inhibits TNF- | [ |
|
| Polypeptide fraction | Inhibits NO in LPS-stimulated macrophage RAW 264.7cells. Inhibit IL-6, TNF- | [ |
|
| Hemocyanin | Increases IFN- | [ |
|
| Lipid extract | Reduces the swelling of paw oedema. Inflammatory mediators (LTB4, PGE 2, and TXB2) and pro-inflammatory cytokines (IL-1, IL-6, INF- | [ |
|
| Zhikang Capsule | Suppresses TNF- | [ |
|
| Marine n-3 polyunsaturated fatty acids | Decreases human T cell spread, slows onset of arthritis, reduces paw swelling, reduces knee joint pathology, modulates a range of immunological reactions associated with RA. | [ |
|
| Sinuleptolide | IL-1 | [ |
| Steroid glycoside carijoside | Neutrophil superoxide and elastase inhibition. | [ | |
|
| Terpene gyrosanolides B & C | Inhibits iNOS expression in macrophages. | [ |
|
| 11-Dehydrosinulariolide | Attenuates 6-OHDA-induced downregulation of TH-immunoreactivity and 6-OHDA-induced upregulation of DJ-1 protein in rat and zebrafish models. | [ |
|
| Klysimplexin sulfoxide (Terpene) & simplexin E | Inhibits expression of COX-2 and iNOS in macrophages. | [ |
|
| Diterpenes | Inhibits NO release and iNOS expression in macrophages. | [ |
|
| Nebrosteroid I (Steroid) | Inhibits iNOS expression in macrophages. | [ |
|
| Polysaccharide | Activates adaptive immune response including T and B cells. | [ |
|
| Dermatan sulfate (Polysaccharide) | Lymphocyte and macrophage, as well as TNF- | [ |
|
| Durumhemiketalolide (Terpene) | Inhibits expression of macrophage COX-2 and iNOS. | [ |
|
| Lemnalol | Inhibits spinal TNF- | [ |
|
| Glycolipid & sarcoehrenosides | Inhibits iNOS expression in macrophages. | [ |
|
| Sarcocrassocolides A & B (Terpene) | Inhibits iNOS expression in macrophages. | [ |
|
| Rossinones A & B (Terpene) | Inhibits neutrophil superoxide. | [ |
| Chabrosterol (Steroid) | Inhibits iNOS and COX-2 expression in macrophages. | [ | |
|
| Symbiopolyol (Polyketide sulfate) | Inhibited expression of inducible vascular cell adhesion molecule-1, which binds to leukocytes in early inflammation stages. | [ |
| Shellfish & finfish sp. | Docosahexaenoic acid | Inhibits carrageenan-induced microglial activation, p38 MAPK phosphorylation, and | [ |
CHOP, C/EBP homologous protein; COX, cyclooxygenase; HIV, human immunodeficiency virus; IgE, immunoglobulin E; IL, interleukin; iNOS, inducible nitric oxide synthase; LKB4; leukotriene B4; MAPK; mitogen-activated protein kinase; MHC, major histocompatibility complex; NF-kB, nuclear factor-κB; NO, nitric oxide; PGE2, prostaglandin E2; PMNs, polymorphonuclear neutrophils; PLA2, phospholipase A; TLR, toll-like receptor; TNF, tumor necrosis factor; TPA, 12-O-tetradecanoylphorbol13-acetate; TXB2, thromboxane B2.
Figure 2Schematic diagram showing omics data analysis and genome-scale metabolic modelling for improvement of production.